10 Best Low Priced Biotech Stocks to Buy Now

7. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Stock Price: $9.50

Number of Hedge Fund Holders: 36

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes innovative small molecules and antibody therapies as a novel treatment approach for inflammatory conditions, cancer, and other challenging diseases.

On April 14, Needham analyst Gil Blum maintained their bullish stance on Nurix Therapeutics, Inc. (NASDAQ:NRIX), giving it a Buy rating due to its promising preclinical data and innovative capabilities. The company’s DEL-AI discovery platform can identify novel binders for a range of targets, bringing a positive light to its operations. Blum has a price target of $27 on NRIX stock.

Nurix Therapeutics, Inc.’s (NASDAQ:NRIX) BRAF degrader, NRX-0305, is also effective in targeting multiple mutation classes and has the potential to penetrate the central nervous system. The analyst further reasoned that the compound showed synergistic effects when used with other treatments.

These advancements thus position Nurix Therapeutics, Inc. (NASDAQ:NRIX) to develop groundbreaking therapies, justifying the Buy rating. On May 7, Piper Sandler analyst Biren Amin also reiterated a Buy rating on the company, setting a price target of $35.00. The company is seventh on our list of the best low-priced biotech stocks to invest in.